NBIO News and Press, Nascent Biotech From 08/11/20

SAN DIEGO, CA / ACCESSWIRE / August 11, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO) Announced today that It has significantly reduced its liabilities through stock conversion and payment of accrued liabilities. The reduction was achieved through the conversion of $1,600,000 in debt to equity a...

August 4, 2020 Palm Beach, FL – August 4, 2020 – It seems lately, that news on a vaccine (or vaccines) for the global health crisis, project new possibilities moving quickly to the final solution.  The number of vaccines in development seems to be growing daily....

SAN DIEGO, CA / ACCESSWIRE / August 4, 2020 / Nascent Biotech, Inc (OTCQB:NBIO), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat cancers and viral infections, has participated in the recent expert panel discussion entitled "BCG: a therapeuti...

July 28, 2020 Palm Beach, FL – July 28, 2020 – As the global pandemic caused by the coronavirus SARS-CoV-2 continues, researchers are working at unprecedented speed to produce new treatments and vaccines. Much work has focused on studying antibodies from the blood of...

SAN DIEGO, CA / ACCESSWIRE / July 28, 2020 / Nascent Biotech, Inc. (OTCQB:NBIO), announced today it has entered into a research collaboration with Syracuse University to further the development of Pritumumab, a unique monoclonal antibody that binds to cell-surface vimentin, for potential use...

SAN DIEGO, June 24, 2020 (GLOBE NEWSWIRE) -- Nascent Biotech, Inc. (OTC: NBIO) announced today that it has appointed Dr. Navpaul Singh MD as Chief Medical Consultant in charge of research into Pritumumab’s use with viral infections, including COVID-19. Dr. Singh stated, “Wi...

June 17, 2020 Palm Beach, FL – June 17, 2020 – The race for a vaccine to end the current global healthcare crisis has ramped-up even more with a second wave of outbreaks starting to appear. The White House’s Office of Science and Technology Policy said in a st...

SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) -- Nascent Biotech, Inc. (OTCQB: NBIO) , today announced after receiving early In-Vitro study results Pritumumab, (PTB), will be advanced to laboratory-based animal studies. Nascent founder and Advisory Board Chairman Dr. Mark Glassy commented, &#x...

June 3, 2020 Palm Beach, FL – June 3, 2020 – Researchers have been working furiously to identify medications to combat the novel coronavirus that causes COVID-19. While there are no definitive answers yet, the Food and Drug Administration (FDA) has authoriz...

SAN DIEGO, CA / ACCESSWIRE / June 3, 2020 / Nascent Biotech, Inc (OTCQB:NBIO) (the "Company" or "Nascent") is pleased to provide a corporate update and summary with a recent interview the Company's CEO, Sean Carrick, presented on SNN Network. The complete interview may be seen on the SNN Net...